I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to the cardiovascular candidate. The rights will be transferred from ...

Sanofi is increasing its R&D presence in China, announcing plans to open a global research hub focused on data analysis in Chengdu. The French firm said this confirms China as the “third pillar ...

But another geographic deal — like the one Cytokinetics recently struck with Bayer in Japan and with Corxel/Sanofi in Greater China — hasn't been disclosed. Aficamten, a small-molecule tablet ...

This will be Sanofi's largest single investment in China since entering the country in 1982. Sanofi has not been alone ...

CORXEL, formerly Ji Xing, in 2020, acquired the rights to develop and commercialize aficamten in Greater China from Cytokinetics. Sanofi will now acquire CORXEL's rights relating to aficamten in ...

Sanofi will now acquire CORXEL’s rights relating to aficamten in Greater China for an undisclosed amount. Cytokinetics remains eligible to receive up to $150 million in development and ...

Under the Health Silk Road, Beijing has embedded itself as a critical partner across Africa’s entire healthcare ecosystem, ...